Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification

MLA

Wataru Fukumoto, et al. “Development of a Novel Treatment Based on PKMYT1 Inhibition for Cisplatin-Resistant Bladder Cancer with MiR-424-5p-Dependent Cyclin E1 Amplification.” BMC Cancer, vol. 24, no. 1, Oct. 2024, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s12885-024-13109-5.

APA

Wataru Fukumoto, Shunsuke Okamura, Motoki Tamai, Junya Arima, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoshi Sugita, Ryosuke Matsushita, Shuichi Tatarano, Yasutoshi Yamada, Masayuki Nakagawa, Hideki Enokida, & Hirofumi Yoshino. (2024). Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification. BMC Cancer, 24(1), 1–10. https://doi.org/10.1186/s12885-024-13109-5

Chicago

Wataru Fukumoto, Shunsuke Okamura, Motoki Tamai, Junya Arima, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, et al. 2024. “Development of a Novel Treatment Based on PKMYT1 Inhibition for Cisplatin-Resistant Bladder Cancer with MiR-424-5p-Dependent Cyclin E1 Amplification.” BMC Cancer 24 (1): 1–10. doi:10.1186/s12885-024-13109-5.